239 related articles for article (PubMed ID: 10961881)
1. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
Taube J; Halsall D; Baglin T
Blood; 2000 Sep; 96(5):1816-9. PubMed ID: 10961881
[TBL] [Abstract][Full Text] [Related]
2. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
[TBL] [Abstract][Full Text] [Related]
3. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
4. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.
Tabrizi AR; Zehnbauer BA; Borecki IB; McGrath SD; Buchman TG; Freeman BD
J Am Coll Surg; 2002 Mar; 194(3):267-73. PubMed ID: 11893129
[TBL] [Abstract][Full Text] [Related]
5. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.
Hermida J; Zarza J; Alberca I; Montes R; López ML; Molina E; Rocha E
Blood; 2002 Jun; 99(11):4237-9. PubMed ID: 12010835
[TBL] [Abstract][Full Text] [Related]
7. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
8. Major bleeding caused by warfarin in a genetically susceptible patient.
Bloch A; Ben-Chetrit E; Muszkat M; Caraco Y
Pharmacotherapy; 2002 Jan; 22(1):97-101. PubMed ID: 11794436
[TBL] [Abstract][Full Text] [Related]
9. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.
Kealey C; Chen Z; Christie J; Thorn CF; Whitehead AS; Price M; Samaha FF; Kimmel SE
Pharmacogenomics; 2007 Mar; 8(3):217-25. PubMed ID: 17324110
[TBL] [Abstract][Full Text] [Related]
10. Warfarin dose requirement and CYP2C9 polymorphisms.
Halkin H; Lubetsky A
Lancet; 1999 Jun; 353(9168):1972-3. PubMed ID: 10371596
[No Abstract] [Full Text] [Related]
11. Pharmacogenetics of warfarin elimination and its clinical implications.
Takahashi H; Echizen H
Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
[TBL] [Abstract][Full Text] [Related]
12. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
[TBL] [Abstract][Full Text] [Related]
14. CYP2C9 polymorphism and warfarin dose requirements.
Daly AK; Day CP; Aithal GP
Br J Clin Pharmacol; 2002 Apr; 53(4):408-9. PubMed ID: 11966680
[No Abstract] [Full Text] [Related]
15. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
16. [Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin].
Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Sychev DA; Dobrovol'skiĭ AB; Panchenko EP
Kardiologiia; 2008; 48(3):52-7. PubMed ID: 18429757
[TBL] [Abstract][Full Text] [Related]
17. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
18. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
19. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
Yamazaki H; Inoue K; Shimada T
Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
[TBL] [Abstract][Full Text] [Related]
20. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
Redman AR
Pharmacotherapy; 2001 Feb; 21(2):235-42. PubMed ID: 11213860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]